Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Dulaglutide (Trulicity)30 residuesHGEGTFTSDVSSYLEGQAAKEFIAWLVKGREach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Trulicity, LY2189265
A 12% reduction in heart attacks, strokes, and cardiovascular death over 5.4 years. That's what the REWIND trial landed on in 9,901 adults with type 2 diabetes. Dulaglutide (Trulicity) is Eli Lilly's once-weekly GLP-1 receptor agonist, delivered through a pre-filled pen that needs zero reconstitution and zero needle attachment. HbA1c drops range from 1.0 to 1.87% across the AWARD trial program, with modest weight loss of 1.5 to 4.6 kg depending on dose. It won't match semaglutide or tirzepatide for weight loss. But for T2D patients who want proven cardiovascular protection in the simplest delivery format available, dulaglutide still holds ground.
A 12% cut in cardiovascular death, heart attack, and stroke. That's what 9,901 people in the REWIND trial got over a median 5.4 years of once-weekly dulaglutide [1]. About 69% of those participants had no prior cardiovascular disease. That makes it the first GLP-1 receptor agonist to show benefit in a primary prevention population. Dulaglutide (brand name Trulicity, CAS 923950-08-7) is a fusion protein built by Eli Lilly. Two GLP-1 analog sequences connect to a modified human IgG4 Fc domain, forming a homodimer of roughly 63 kDa. That Fc domain slows renal clearance enough to push the half-life to about 5 days. One injection per week, delivered through a pre-filled pen with a hidden needle. On the blood sugar side, HbA1c reductions run 1.0 to 1.87% depending on dose. The AWARD-11 trial [2] tested the higher 3.0 mg and 4.5 mg strengths in 3,623 adults; the top dose pulled HbA1c down 1.87% and weight down 4.6 kg at 36 weeks. Most community users stay at 0.75 to 1.5 mg. GI tolerability drops off sharply above that. The honest comparison: semaglutide beats dulaglutide for both HbA1c reduction and weight loss at equivalent weekly doses (SUSTAIN-7)[3]. Tirzepatide pushes even further ahead. Dulaglutide's real selling points are the pen's simplicity (no reconstitution, no needle attachment, no dose dialing) and a mature safety profile backed by 10+ years of post-marketing data. For T2D patients who prioritize convenience and have solid cardiovascular reasons to be on a GLP-1, it fills a clear role.
Dulaglutide binds GLP-1 receptors on pancreatic beta cells. That triggers adenylyl cyclase, raising intracellular cAMP. The downstream result is glucose-dependent insulin secretion, meaning insulin release only ramps up when blood sugar is raised. This glucose-dependence is why hypoglycemia risk with dulaglutide alone stays low. The molecule also suppresses glucagon from alpha cells after meals. Glucagon normally tells the liver to dump glucose into the bloodstream; blocking that postprandial spike tightens glucose control in a way that insulin alone can't match. Gastric emptying slows down too. Food moves through the stomach more gradually, blunting the postprandial glucose surge that spikes blood sugar 30 to 90 minutes after eating. This same mechanism is why nausea is the most common side effect during dose titration. The appetite piece involves hypothalamic satiety centers. GLP-1 receptors in the brain reduce hunger signaling, which drives the modest weight loss seen in the AWARD trials. What makes dulaglutide last a full week comes down to its structure. The GLP-1 analog portion is 90% homologous to native GLP-1, but native GLP-1 gets destroyed by DPP-4 enzymes within minutes. Dulaglutide's modified IgG4 Fc domain (forming a ~63 kDa homodimer) protects the active portion from enzymatic breakdown and reduces renal clearance. The resulting half-life sits at approximately 120 hours. Steady-state plasma levels are reached within 2 to 3 weeks of weekly dosing (Geiser et al., Clin Pharmacokinet 2016)[4]. Subcutaneous bioavailability is dose-dependent: roughly 65% at the 0.75 mg dose and 47% at 1.5 mg.
FDA-approved once-weekly GLP-1 RA for T2D. Strong evidence for HbA1c reduction (1.0–1.87% across AWARD program) and cardiovascular risk reduction (REWIND: HR 0.88 vs placebo over 5.4 years). Modest weight loss (1.5–4.6 kg dose-dependent). Strong renal protective signal in CKD subgroups (AWARD-7; REWIND post-hoc)[5].
REWIND trial (PMID 31189511): n=9,901, median 5.4-year follow-up, MACE HR 0.88 (95% CI 0.79–0.99)
Head-to-head data vs semaglutide (SUSTAIN-7, PMID 29141884) shows semaglutide superior for HbA1c reduction and weight loss at equivalent weekly doses. No approved indication for obesity without T2D. 4.5 mg dose approved 2020; long-term outcomes at higher doses not yet established beyond AWARD-11.
Well-regarded for T2D management with the convenience of a no-reconstitution pen. Users frequently switch to semaglutide or tirzepatide when more weight loss is desired. GI side effects at 3–4.5 mg strongly polarize ratings.
Community protocols closely mirror the FDA label. Off-label weight-loss use is minimal: most users are prescribed for T2D. The primary community divergence is dose ceiling: many users stop at 1.5 mg due to GI tolerability while FDA supports titration to 4.5 mg.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.75mg | Weekly |
| Moderate | 1.5mg | Weekly |
| Aggressive | 4.5mg | Weekly |
Trulicity ships ready to inject. No vials, no bacteriostatic water, no syringe math. Each pen contains a single fixed dose with an integrated needle. Store pens in the fridge at 2 to 8 degrees Celsius. If you need to travel, they're stable at room temperature (up to 30 degrees Celsius) for 14 days. Don't freeze them. Before injection, let a cold pen sit out for about 30 minutes. Cold pens are the number one cause of activation failures and injection site stinging. Look through the pen window to confirm the solution is clear and colorless. Cloudy or discolored liquid means toss it. Four dose strengths exist: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg. Each pen is a single strength with no volume to measure or calculate. Start at 0.75 mg weekly. If blood sugar targets aren't met after four weeks, step up to 1.5 mg. Most community users stay at 1.5 mg long-term; that's the sweet spot between efficacy and GI tolerability for the majority. Don't rush dose escalation. GI side effects spike with every step up, and giving your gut 4 weeks to adapt makes the difference between tolerating the drug and quitting it.
Dulaglutide is used continuously as a chronic therapy for type 2 diabetes. No cycling is required or recommended. Discontinuation should be discussed with a prescribing physician, as glycemic control and cardiovascular benefits depend on ongoing use.
Dulaglutide is chronic disease therapy, not a research peptide protocol. Continuous use is required to maintain glycemic control, HbA1c reduction, and cardiovascular protection. Discontinuation causes glycemic rebound within ~2 weeks (5-day half-life) and loss of CV benefits demonstrated in REWIND. There is no cycling rationale. Treatment continues indefinitely unless a medical contraindication emerges or the patient switches to a different agent.
Or use the universal Peptide Calculator for any peptide.
Expected: HbA1c reduction of 1.0–1.4% from baseline; fasting glucose improvement within 2–4 weeks; weight loss of 1.5–3 kg
Monitor: Check HbA1c at 3 months. Monitor eGFR and blood pressure annually. Self-monitor BG per clinician guidance.
Let it sit at room temperature for about 30 minutes. Cold pens sting more and are harder to activate.
The solution should be clear and colorless. Do not use if cloudy, discolored, or if particles are floating in it.
Rotate to a different area each week. Clean the site with an alcohol swab and let it dry.
This unlocks the device.
Press and hold the green injection button. You'll hear a first click (the needle inserts). Keep holding for about 10 seconds until you hear a second click (injection complete).
Check the window to confirm the gray plunger has moved. If it hasn't, the full dose may not have been delivered.
Each pen is single-use. Never reuse or share pens.
Timing: inject on the same day each week. Any time of day works, with or without food. If you need to change your injection day, the last dose must have been at least 3 days prior.
No syringe units to calculate. No reconstitution math. The pen delivers a fixed dose. That's one of dulaglutide's biggest practical advantages over vial-and-syringe GLP-1 options.
Standard-of-care first-line T2D combination. Complementary mechanisms: metformin reduces hepatic glucose output; dulaglutide increases glucose-dependent insulin secretion and suppresses glucagon. No pharmacokinetic interaction.
Additive glycemic and cardiovascular/renal benefits. SGLT2 inhibitors provide independent heart failure and renal protection not covered by GLP-1 agonists. Combination endorsed in ADA/EASD guidelines for T2D patients with HFrEF or CKD.
Standard approved doses of each agent; no dose adjustment required
Used for T2D patients not meeting HbA1c targets on oral agents + GLP-1 RA alone. Dulaglutide reduces required insulin dose by suppressing postprandial glucagon and slowing gastric emptying.
Titrate insulin to fasting BG target; monitor for hypoglycemia: insulin dose reduction often needed when adding dulaglutide
Occasionally combined in clinical practice. Incremental HbA1c benefit is small (~0.2–0.4%) since DPP-4 inhibitors upregulate endogenous GLP-1, partially overlapping with dulaglutide's mechanism. Not guideline-preferred over escalating dulaglutide dose.
Duplicate GLP-1 receptor agonist mechanism. Combining two GLP-1 RAs provides no additional efficacy and substantially increases GI side effects. Switch is appropriate; concurrent use is not.
Do not combineDuplicate GLP-1 receptor agonist mechanism. Same clinical rationale as semaglutide: no additive benefit, amplified GI adverse effects.
Do not combineTirzepatide is a dual GIP/GLP-1 agonist: the GLP-1 component duplicates dulaglutide's mechanism. Concurrent use not studied; expected to amplify GI side effects without additional therapeutic benefit.
Do not combineAdditive hypoglycemia risk, especially in elderly or renally impaired patients. If combination required, reduce sulfonylurea dose and monitor closely.
Pricing updated 2026-04-09
The FDA label carries a boxed warning for medullary thyroid carcinoma. In rodent studies, GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumors. Whether this applies to humans remains unknown after more than a decade of post-marketing surveillance. No confirmed cases in humans have been attributed to GLP-1 receptor agonists. Still, dulaglutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Report any neck mass, hoarseness, or difficulty swallowing immediately. Pancreatitis is the second serious concern. Cases are rare but documented across the GLP-1 class. Severe persistent abdominal pain radiating to the back warrants stopping the drug and getting amylase and lipase checked. Do not restart dulaglutide after confirmed pancreatitis. Gastrointestinal side effects are the daily reality for most patients during titration. Nausea hits 8 to 21% depending on dose. Diarrhea runs 8 to 12%. Vomiting, abdominal pain, and decreased appetite round out the GI profile. These effects are dose-dependent and usually peak during the first four weeks at each dose level. Most people tolerate 0.75 mg and 1.5 mg without major issues. The jump to 3.0 mg and 4.5 mg is where things get harder. In AWARD-11 data, nausea resurgence at 3.0 mg hit 20 to 35% of participants during the titration window. Vomiting climbed to 10 to 15%. Community dropout at the higher doses is high specifically because of renewed GI symptoms. Community reviews on Drugs.com (n=980, average rating 5.3/10) and WebMD (n=271, average 3.3/5) confirm this pattern. Users at 0.75 to 1.5 mg report satisfaction with glycemic control and manageable side effects. Users who escalated to 3.0 mg or 4.5 mg report renewed nausea that sometimes prompted switching to a different GLP-1. Hypoglycemia risk with dulaglutide alone is low because insulin secretion is glucose-dependent. That changes when insulin or sulfonylureas enter the picture. Dose reductions of the concurrent insulin or sulfonylurea are typically needed. Elderly patients and those with renal impairment face higher risk in combination therapy. Injection site reactions (bruising, stinging, induration) show up more in community reports than in clinical trial data. The pen's auto-injection mechanism can feel abrupt. Letting the pen warm to room temperature for 30 minutes before use helps. Rotating injection sites across abdomen, thigh, and upper arm on a weekly cycle reduces recurrence. Slowed gastric emptying can delay absorption of oral medications taken around the same time. Warfarin and levothyroxine absorption may shift enough to warrant closer monitoring of INR and thyroid levels during initiation or dose changes. Pregnancy is a hard stop. Animal data shows potential fetal harm. The FDA label recommends discontinuing at least 2 months before planned pregnancy. The 5-day half-life means meaningful drug levels persist for weeks after the last injection. When to contact a physician: persistent severe abdominal pain, neck mass or hoarseness, signs of anaphylaxis (difficulty breathing, swelling of face or throat), or repeated hypoglycemic episodes when used with insulin.
Verify Dulaglutide (Trulicity) dosing and safety with a second opinion
Brand-name FDA-approved product (Trulicity, Eli Lilly) in pre-filled single-use pen with integrated needle. No reconstitution, no vial drawing, no mixing. Full GMP manufacturing, lot testing, and cold-chain supply. No compounded dulaglutide market (not on FDA shortage list; patent-protected). No known counterfeiting market.
| Test | When | Target |
|---|---|---|
| HbA1c | Every 3 months until at goal, then every 6 months | <7.0% for most adults with T2D per ADA 2024 guidelines; individualize per patient risk |
| Fasting plasma glucose / CGM | Ongoing self-monitoring per clinician recommendation | 80–130 mg/dL fasting (ADA 2024) |
| eGFR (estimated glomerular filtration rate) | Annually; more frequently if eGFR <60 mL/min/1.73m² | >60 mL/min/1.73m² (Stage 3+ CKD: monitor every 3–6 months) |
| UACR (urine albumin-to-creatinine ratio) | Annually | <30 mg/g (normal); 30–300 mg/g = microalbuminuria; >300 mg/g = macroalbuminuria |
| Lipid panel | Annually | LDL <70 mg/dL for patients with established CVD |
| Thyroid palpation / TSH if symptomatic | At initiation; repeat only if symptoms arise (neck mass, dysphagia, hoarseness, dyspnea) | — |
| Amylase / lipase | Only if persistent severe abdominal pain: not routine monitoring | — |
| Blood pressure and body weight | Each clinical visit | — |
Primary efficacy marker for glycemic control; guides dose escalation decisions
Real-time glycemic feedback; detect hypoglycemia if on concurrent insulin or sulfonylurea
Dulaglutide has renal protective effects documented in REWIND post-hoc; no dose adjustment needed but monitor progression
Tracks renal protection benefit: dulaglutide reduces new macroalbuminuria onset (REWIND renal post-hoc, PMID 37343574)
GLP-1 RAs have modest favorable effects on lipids; monitor cardiovascular risk markers in high-CVD-risk population
Boxed warning: risk of medullary thyroid carcinoma in rodent studies; clinical risk in humans not established but warrants symptom vigilance
Rare pancreatitis association with GLP-1 RAs; lab evaluation only if clinical suspicion
GLP-1 RAs associated with modest BP reduction; weight tracks therapeutic response and metabolic benefit
Starting dose. GI side effects (nausea, diarrhea) are most common during this period and typically mild. Early blood sugar improvements begin. HbA1c reduction of approximately 0.5-0.7% expected. Appetite changes may start.
First dose increase if glycemic targets are not met. GI effects often lessen as the body adjusts. HbA1c reductions of approximately 1.0-1.2% from baseline. Mild weight loss of 1-2 kg may occur.
Higher dose option available since AWARD-11. Further HbA1c reduction (up to 1.5% from baseline). Weight loss becomes more apparent. Steady-state drug levels are well established by this point.
Maximum dose. AWARD-11 showed HbA1c reductions up to 1.87% and weight loss of 4.6 kg at 36 weeks with 4.5mg. Fasting glucose and postprandial glucose control optimize. GI side effects generally resolved.
Long-term maintenance. REWIND trial showed sustained cardiovascular protection over 5.4 years of use. HbA1c and weight benefits are maintained while on therapy. Renal protective effects observed with prolonged use.
Weeks 1 through 4 (0.75 mg): Steady-state builds over the first 2 to 3 weeks given the 5-day half-life. Fasting glucose starts dropping. HbA1c trends downward, with roughly 0.5 to 0.7% reduction expected by the end of this phase. Appetite changes often show up within the first 1 to 2 weeks. Nausea hits 8 to 14% of users during this stretch; diarrhea runs 8 to 12%. Most people handle 0.75 mg without major issues. Community users frequently mention earlier satiety at meals and occasional injection site bruising. Weeks 5 through 12 (1.5 mg): This is where most community users stay long-term. HbA1c reduction reaches 1.0 to 1.4% from baseline at 26 weeks (AWARD-6 data, vs liraglutide). Weight loss of 1.5 to 3 kg becomes visible. GI side effects from the dose step usually fade as the gut adapts. Nausea drops to about 5 to 8%. Some users develop constipation at this stage. Blood sugar improvements are consistent on CGM and fingerstick monitoring alike. Weeks 13 through 24 (3.0 mg if escalated): Incremental HbA1c drop of about 0.4 to 0.5% beyond the 1.5 mg result. Weight loss increases to roughly 3.5 kg. Nausea comes back hard during dose escalation (20 to 35% of users), with vomiting in 10 to 15% and diarrhea in 15 to 20%. Community dropout at this dose is high. Those who push through report better postprandial glucose control. This is the dose where many patients start comparing to Ozempic or Mounjaro. Weeks 25 and beyond (4.5 mg maximum): AWARD-11 [2] tracked peak HbA1c reduction of 1.87% and weight loss of 4.6 kg at 36 weeks. Fasting and postprandial glucose reach their best numbers here. GI effects are generally resolving by week 36. Community reports at this dose are limited because GI tolerability keeps most people at lower doses. Those who reach 4.5 mg tend to report the strongest metabolic outcomes. Year 1 and beyond: REWIND followed participants for a median of 5.4 years. Cardiovascular protection held (HR 0.88 for MACE) across the full follow-up. HbA1c and weight benefits stay stable with continued use. Renal protection builds over years of treatment (slowed eGFR decline, reduced new macroalbuminuria per)[5]. Some long-term users switch to semaglutide or tirzepatide for greater weight loss. The Lilly savings card at $25 per month for commercially insured patients keeps adherence high for those who stay on.
Steady-state achieved ~2–3 weeks (5-day half-life). Fasting glucose begins declining. HbA1c trend downward (~0.5–0.7% reduction expected by end of phase). Mild appetite suppression onset.
Most users tolerate 0.75 mg well. Nausea reported but typically mild. Many note reduced appetite and earlier satiety within 1–2 weeks. Injection site bruising occasionally reported.
HbA1c reduction of ~1.0–1.4% from baseline at 26 weeks (AWARD-6, vs liraglutide). Weight loss of 1.5–3 kg. GI side effects diminish as GI adaptation progresses.
Most users plateau here for long-term use: balances efficacy and tolerability. Weight loss visible and appreciated. GI symptoms improved vs initiation phase. Consistent blood sugar improvement on CGM and self-monitoring.
Incremental HbA1c reduction of ~0.4–0.5% over 1.5 mg. Weight loss increases to ~3.5 kg. GI side effects increase with dose escalation but typically transient.
High dropout at 3 mg due to renewed nausea. Users who tolerate this dose report greater weight loss and better postprandial glucose control. This is where many patients begin comparing to Ozempic or Mounjaro.
HbA1c reduction up to 1.87% and weight loss up to 4.6 kg at 36 weeks (AWARD-11, PMID 33397768). Maximum fasting and postprandial glucose control. GI effects generally resolving by week 36.
Few community reports at this dose: GI tolerability limits real-world uptake. Those who reach 4.5 mg report best overall metabolic outcomes. Common comparison point: tirzepatide noted as more effective for weight loss by community.
REWIND: sustained MACE reduction (HR 0.88) over 5.4-year median follow-up. Sustained HbA1c and weight benefit during continued use. Renal protective effect documented (slowed eGFR decline, reduced new macroalbuminuria onset per PMID 37343574).
Long-term users report stable glycemic control and weight maintenance. Some community attrition as patients switch to semaglutide or tirzepatide for greater weight loss. Lilly savings card significantly improves adherence at $25/month for commercially insured.
Source: FDA Prescribing Information (Trulicity), Section 12.3; Geiser et al. Clin Pharmacokinet 2016 PMID:26507721
Loading the interactive decay curve.
Dulaglutide (Trulicity) holds full FDA approval for two indications: type 2 diabetes in adults and reduction of major adverse cardiovascular events in adults with T2D and established cardiovascular disease or multiple cardiovascular risk factors. It is not approved for type 1 diabetes, weight loss without T2D, or pediatric use. Trulicity is manufactured by Eli Lilly. It requires a prescription in the United States and most international markets. Patent protection extends through approximately 2031; biosimilar entry is projected around 2033 to 2034. No legitimate compounded dulaglutide exists. The molecule is a large biologic that cannot be replicated by compounding pharmacies, and it is not on the FDA drug shortage list. Any product marketed as compounded dulaglutide should be treated as mislabeled or counterfeit. For athletes: GLP-1 receptor agonists are not currently listed as prohibited substances by WADA. Verify current status with your sport's anti-doping authority before use. Purchase only from licensed US pharmacies. Verify Trulicity labeling with Eli Lilly Rx markings on the carton and pen. This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.
Peptide Schedule Research TeamReviewed Apr 20268 Citations
